About
About GW Pharmaceuticals plc
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Visit company website
5 years, 5 months ago
GW Pharmaceuticals plc is currently in a long term uptrend where the price is trading 37.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
GW Pharmaceuticals plc's total revenue rose by 35.9% to $148M since the same quarter in the previous year.
Its net income has dropped by 16.8% to $-29M since the same quarter in the previous year.
Finally, its free cash flow grew by 105.9% to $2M since the same quarter in the previous year.
Based on the above factors, GW Pharmaceuticals plc gets an overall score of 4/5.